Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Canakinumab · 1 trial · 1 indication
Proportion of patients with complete response (based on physician's global assessment on overall autoinflammatory disease activity) at day 7 in the canakinumab treated group as compared to the placebo group
| Arm | Type | Description |
|---|---|---|
| Placebo | PLACEBO_COMPARATOR | - |
| Canakinumab | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Canakinumab | DRUG | 150mg subcutaneous injections on day 0 |
| Placebo | DRUG | 150mg subcutaneous injections on day 0 |
Inclusion Criteria: * Adults (18 years or older) * Informed consent signed and dated * Able to read, understand and willing to sign the informed consent form and abide with study procedures * SchS diagnosis based on diagnostic criteria defined in Appendix * Patients with symptomatic Schnitzler synd...
Canakinumab is an investigational small molecule being studied for the treatment of Schnitzler Syndrome, a rare autoinflammatory condition. It is currently in Phase 2 clinical development. The drug has been evaluated in a completed clinical trial to assess its effects in patients with this syndrome.
Canakinumab targets the interleukin-1 beta pathway, which plays a role in inflammation. By inhibiting this pathway, the drug aims to reduce the inflammatory symptoms associated with Schnitzler Syndrome. This mechanism is central to its potential therapeutic effect in the condition.
Canakinumab is being developed by Pulmonx Corporation, a company traded on the NASDAQ under the ticker symbol LUNG. The company is conducting clinical research to evaluate the drug's safety and efficacy in patients with Schnitzler Syndrome.
Canakinumab is in Phase 2 clinical development for Schnitzler Syndrome. It is an investigational drug and has not yet been approved by regulatory authorities. A Phase 2 clinical trial has been completed to evaluate its effects in this patient population.
Canakinumab has been studied in a completed Phase 2 clinical trial with the identifier NCT01390350, titled "Ilaris® Effects in Schnitzler Syndrome (ILESCH)." This trial enrolled 20 participants in Germany and was a randomized, double-blind, placebo-controlled study.
Canakinumab is also known as Ilaris, as indicated by the clinical trial title "Ilaris® Effects in Schnitzler Syndrome." The drug is being investigated under this brand name in the context of the Phase 2 trial for Schnitzler Syndrome.